FASEB J. Cell Migration Consortium
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by De Souza, A. T.
Right arrow Articles by Jirtle, R. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by De Souza, A. T.
Right arrow Articles by Jirtle, R. L.

The FASEB Journal, Vol 11, 60-67, Copyright © 1997 by The Federation of American Societies for Experimental Biology

REVIEWS

Imprinted genes in liver carcinogenesis

AT De Souza, T Yamada, JJ Mills and RL Jirtle
Department of Safety of Medicines, Zeneca Pharmaceuticals, Macclesfield, Cheshire, United Kingdom.

Each cell contains both maternal and paternal copies of all genes except those that reside on the sex chromosomes. However, because of a phenomenon termed genomic imprinting, not all genes are biallelically expressed. Imprinted genes play an important role in embryogenesis and recently have also been shown to be mechanistically involved in carcinogenesis. The growing list of imprinted genes implicated in tumor formation includes both a growth factor gene, insulin-like growth factor 2 (IGF2), and a receptor gene, mannose 6-phosphate/insulin-like growth factor 2 receptor (M6P/IGF2R). Elevated expression of IGF2 is often found in tumors, and loss of imprinting is one mechanism by which its expression is deregulated. The M6P/IGF2R functions in the inactivation of the mitogen IGF2 and in the activation of the growth inhibitor, transforming growth factor beta. Recently, a high frequency of loss of heterozygosity with concomitant mutations in the remaining allele has been shown to occur at the M6P/IGF2R locus (i.e., 6q26-q27) in both human liver and breast tumors, suggesting that this gene functions as a tumor suppressor. Expression of the M6P/IGF2R gene is biallelic in most humans but is monoallelic in mice. This species difference in M6P/IGF2R gene imprinting provides one plausible explanation for the enhanced sensitivity of mice to tumor formation. Furthermore, these findings suggest that species differences in the imprinted status of genes mechanistically involved in tumor formation should be factored into human carcinogenesis risk assessment models when extrapolating results from mice to humans.


This article has been cited by other articles:


Home page
 Proc. Natl. Acad. Sci. USAHome page
C.-Q. Zhu, S. N. Popova, E. R. S. Brown, D. Barsyte-Lovejoy, R. Navab, W. Shih, M. Li, M. Lu, I. Jurisica, L. Z. Penn, et al.
Integrin {alpha}11 regulates IGF2 expression in fibroblasts to enhance tumorigenicity of human non-small-cell lung cancer cells
PNAS, July 10, 2007; 104(28): 11754 - 11759.
[Abstract] [Full Text] [PDF]

Home page
 Nucleic Acids ResHome page
Z. Huang, Y. Wen, R. Shandilya, J. R. Marks, A. Berchuck, and S. K. Murphy
High throughput detection of M6P/IGF2R intronic hypermethylation and LOH in ovarian cancer
Nucleic Acids Res., January 23, 2006; 34(2): 555 - 563.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Kaneda and A. P. Feinberg
Loss of Imprinting of IGF2: A Common Epigenetic Modifier of Intestinal Tumor Risk
Cancer Res., December 15, 2005; 65(24): 11236 - 11240.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
K. A. Jessen, N. M. English, J. Yu Wang, S. Maliartchouk, S. P. Archer, L. Qiu, R. Brand, J. Kuemmerle, H.-Z. Zhang, K. Gehlsen, et al.
The discovery and mechanism of action of novel tumor-selective and apoptosis-inducing 3,5-diaryl-1,2,4-oxadiazole series using a chemical genetics approach
Mol. Cancer Ther., May 1, 2005; 4(5): 761 - 771.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
T. H. Vu, T. Li, and A. R. Hoffman
Promoter-restricted histone code, not the differentially methylated DNA regions or antisense transcripts, marks the imprinting status of IGF2R in human and mouse
Hum. Mol. Genet., October 1, 2004; 13(19): 2233 - 2245.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol PatholHome page
R.R. Maronpot, G. Flake, and A. J. Huff
Relevance of Animal Carcinogenesis Findings to Human Cancer Predictions and Prevention
Toxicol Pathol, January 1, 2004; 32(1_suppl): 40 - 48.
[Abstract] [PDF]

Home page
 EndocrinologyHome page
Y. Yang, T. Li, T. H. Vu, G. A. Ulaner, J.-F. Hu, and A. R. Hoffman
The Histone Code Regulating Expression of the Imprinted Mouse Igf2r Gene
Endocrinology, December 1, 2003; 144(12): 5658 - 5670.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
B. S. Schaffer, M.-F. Lin, J. C. Byrd, J. H. Y. Park, and R. G. MacDonald
Opposing Roles for the Insulin-Like Growth Factor (IGF)-II and Mannose 6-Phosphate (Man-6-P) Binding Activities of the IGF-II/Man-6-P Receptor in the Growth of Prostate Cancer Cells
Endocrinology, March 1, 2003; 144(3): 955 - 966.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
V. Leksa, S. Godar, M. Cebecauer, I. Hilgert, J. Breuss, U. H. Weidle, V. Horejsi, B. R. Binder, and H. Stockinger
The N Terminus of Mannose 6-Phosphate/Insulin-like Growth Factor 2 Receptor in Regulation of Fibrinolysis and Cell Migration
J. Biol. Chem., October 18, 2002; 277(43): 40575 - 40582.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. K. Hancock, D. J. Haskins, G. Sun, and N. M. Dahms
Identification of Residues Essential for Carbohydrate Recognition by the Insulin-like Growth Factor II/Mannose 6-Phosphate Receptor
J. Biol. Chem., March 22, 2002; 277(13): 11255 - 11264.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. Chen, S. Pajovic, A. Duckett, V. D. Brown, J. A. Squire, and B. L. Gallie
Genomic Amplification in Retinoblastoma Narrowed to 0.6 Megabase on Chromosome 6p Containing a Kinesin-like Gene, RBKIN
Cancer Res., February 1, 2002; 62(4): 967 - 971.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
E. Parrott, M. Butterworth, A. Green, I. N. H. White, and P. Greaves
Adenomyosis--A Result of Disordered Stromal Differentiation
Am. J. Pathol., August 1, 2001; 159(2): 623 - 630.
[Abstract] [Full Text]

Home page
 Mol. Pathol.Home page
J-G Scharf, F Dombrowski, and G Ramadori
The IGF axis and hepatocarcinogenesis
Mol. Pathol., June 1, 2001; 54(3): 138 - 144.
[Abstract] [Full Text]

Home page
 Cancer Res.Home page
K. Lorenzo, P. Ton, J. L. Clark, S. Coulibaly, and L. Mach
Invasive Properties of Murine Squamous Carcinoma Cells: Secretion of Matrix-degrading Cathepsins Is Attributable to a Deficiency in the Mannose 6-Phosphate/Insulin-like Growth Factor II Receptor
Cancer Res., August 1, 2000; 60(15): 4070 - 4076.
[Abstract] [Full Text]

Home page
 Cancer Res.Home page
G. R. Devi, A. T. De Souza, J. C. Byrd, R. L. Jirtle, and R. G. MacDonald
Altered Ligand Binding by Insulin-like Growth Factor II/Mannose 6-Phosphate Receptors Bearing Missense Mutations in Human Cancers
Cancer Res., September 1, 1999; 59(17): 4314 - 4319.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J. C. Byrd, G. R. Devi, A. T. De Souza, R. L. Jirtle, and R. G. MacDonald
Disruption of Ligand Binding to the Insulin-like Growth Factor II/Mannose 6-Phosphate Receptor by Cancer-associated Missense Mutations
J. Biol. Chem., August 20, 1999; 274(34): 24408 - 24416.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
C. J. Kemp
Comparative Hepatocellular Cancer Genetics
Am. J. Pathol., April 1, 1999; 154(4): 975 - 977.
[Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. Costello, R. C. Baxter, and C. D. Scott
Regulation of Soluble Insulin-Like Growth Factor II/Mannose 6-Phosphate Receptor in Human Serum: Measurement by Enzyme-Linked Immunosorbent Assay
J. Clin. Endocrinol. Metab., February 1, 1999; 84(2): 611 - 617.
[Abstract] [Full Text]

Home page
 BloodHome page
Y. Hamano, S. Hirose, A. Ida, M. Abe, D. Zhang, S. Kodera, Y. Jiang, J. Shirai, Y. Miura, H. Nishimura, et al.
Susceptibility Alleles for Aberrant B-1 Cell Proliferation Involved in Spontaneously Occurring B-Cell Chronic Lymphocytic Leukemia in a Model of New Zealand White Mice
Blood, November 15, 1998; 92(10): 3772 - 3779.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
G. R. Devi, J. C. Byrd, D. H. Slentz, and R. G. MacDonald
An Insulin-Like Growth Factor II (IGF-II) Affinity-Enhancing Domain Localized within Extracytoplasmic Repeat 13 of the IGF-II/Mannose 6-Phosphate Receptor
Mol. Endocrinol., November 1, 1998; 12(11): 1661 - 1672.
[Abstract] [Full Text]

Home page
 GeneticsHome page
N. G. C. Smith and L. D. Hurst
Molecular Evolution of an Imprinted Gene: Repeatability of Patterns of Evolution Within the Mammalian Insulin-Like Growth Factor Type II Receptor
Genetics, October 1, 1998; 150(2): 823 - 833.
[Abstract] [Full Text]

Home page
 Proc. Natl. Acad. Sci. USAHome page
T. Yamada, A. T. De Souza, S. Finkelstein, and R. L. Jirtle
Loss of the gene encoding mannose 6-phosphate/insulin-like growth factor II receptor is an early event in liver carcinogenesis
PNAS, September 16, 1997; 94(19): 10351 - 10355.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
I. Ueki, G. T. Ooi, M. L. Tremblay, K. R. Hurst, L. A. Bach, and Y. R. Boisclair
Inactivation of the acid labile subunit gene in mice results in mild retardation of postnatal growth despite profound disruptions in the circulating insulin-like growth factor system
PNAS, June 6, 2000; 97(12): 6868 - 6873.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1997 by The Federation of American Societies for Experimental Biology.